EWHA DrugDesignHouse

Ewha DrugDesignHouse (EDDH) is a South Korean biotechnology company specializing in AI-driven drug discovery and the development of novel small molecule therapeutics. Founded by Professor Young-joo Kwon of Ewha Womans University, the company utilizes a proprietary computational platform to identify and optimize lead compounds for oncology and inflammatory diseases. Their research pipeline is highlighted by next-generation dual topoisomerase inhibitors designed to overcome resistance in solid tumors, including colorectal and lung cancers. By integrating advanced bioinformatics with traditional medicinal chemistry, EDDH focuses on accelerating the transition from hit identification to clinical candidates. The company operates as a university spin-off, leveraging academic expertise to address high unmet medical needs in the global pharmaceutical market.